BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9275104)

  • 21. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report.
    Alonso I; Herreros de Tejada A; Moreno JM; Rubio E; Lucena JL; De la Revilla J; Sánchez Turrión V; Gomez A; Lopez J; Cuervas-Mons V
    Transplant Proc; 2003 Aug; 35(5):1850-1. PubMed ID: 12962821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
    Lenci I; Tariciotti L; Angelico R; Milana M; Signorello A; Manzia TM; Toti L; Tisone G; Angelico M; Baiocchi L
    Clin Transplant; 2023 Jun; 37(6):e14971. PubMed ID: 36928864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation.
    Flowers M; Sherker A; Sinclair SB; Greig PD; Cameron R; Phillips MJ; Blendis L; Chung SW; Levy GA
    Transplantation; 1994 Jul; 58(2):183-92. PubMed ID: 8042236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
    Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
    J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
    Sánchez-Fueyo A; Rimola A; Grande L; Costa J; Mas A; Navasa M; Cirera I; Sánchez-Tapias JM; Rodés J
    Hepatology; 2000 Feb; 31(2):496-501. PubMed ID: 10655276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
    Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
    Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
    Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
    J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention and treatment of HBV reinfection following liver transplantation].
    Yuan G; Duan Y; Wang F; Liang S; Zhu L
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):14-6. PubMed ID: 11856491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B-associated liver cirrhosis as an indication for liver transplantation.
    Jansen PL; Haagsma EB; Klompmaker IJ; Cuypers HT; Karrenbeld A; Gouw AS; Slooff MJ
    Scand J Gastroenterol Suppl; 1995; 212():19-22. PubMed ID: 8578227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.